Search Results

NephroDI Therapeutics (NephroDI), a near-clinical stage pharmaceutical company focusing on kidney disorders, announces a Series A investment from life sciences VC Sound Bioventures.

Sound Bioventures announced a new investment in Theolytics, a UK biotechnology company developing next-generation oncolytic viral therapies.

Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, announced it has successfully closed its latest financing round, raising a total of £19M with the addition of Sound Bioventures as a new investor.

Harmonic Discovery announced an exclusive licensing agreement of a novel small-molecule drug candidate for the treatment of FLT3 mutated acute myeloid leukemia from BioVentures and UC San Francisco.

G1 Therapeutics, Inc., a commercial-stage oncology company, and Deimos Biosciences, a portfolio company of Jupiter Bioventures, announced a global licensing agreement for lerociclib for radioprotective uses.

Alvotech and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC, announced that the Egyptian Drug Authority has approved the manufacturing and distribution of AVT02 a biosimilar for Humira®, which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases, under the trade name Adalimumab-EVA™.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system